Matches in Wikidata for { <http://www.wikidata.org/entity/Q90668330> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q90668330 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q90668330 description "scientific article published on 09 October 2019" @default.
- Q90668330 description "wetenschappelijk artikel" @default.
- Q90668330 description "наукова стаття, опублікована 9 жовтня 2019" @default.
- Q90668330 name "A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis" @default.
- Q90668330 name "A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis" @default.
- Q90668330 type Item @default.
- Q90668330 label "A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis" @default.
- Q90668330 label "A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis" @default.
- Q90668330 prefLabel "A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis" @default.
- Q90668330 prefLabel "A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis" @default.
- Q90668330 P1433 Q90668330-36227FC4-E78E-47C3-8D7C-5A3CF5A45518 @default.
- Q90668330 P1476 Q90668330-5C5F54DD-D927-4748-A8D5-3DF3705D013A @default.
- Q90668330 P2093 Q90668330-166D948F-621F-4AE4-BF9F-22C606347B11 @default.
- Q90668330 P2093 Q90668330-1C6F7487-2727-4846-9A57-27229BEABCA7 @default.
- Q90668330 P2093 Q90668330-495A4C3D-6EF8-46DB-9FF6-24470DA92C15 @default.
- Q90668330 P2093 Q90668330-57676E01-C73A-476B-A503-02DCFF08AFD1 @default.
- Q90668330 P2093 Q90668330-60AA8904-EC3C-43DB-9E3B-9141850617DD @default.
- Q90668330 P2093 Q90668330-8148A05B-8D35-492E-98C4-7842811CB80F @default.
- Q90668330 P2093 Q90668330-8411E5DA-E832-4EE6-9D26-56BBCD09B2DC @default.
- Q90668330 P2093 Q90668330-94714BC0-FA81-4A76-83E5-C48CEB56B4FE @default.
- Q90668330 P2093 Q90668330-97C28967-D6B9-4A53-9EF3-32BCCF1117FB @default.
- Q90668330 P2093 Q90668330-9DD65FFA-26E7-40C6-A21F-E50CF22D4EF3 @default.
- Q90668330 P2093 Q90668330-BE3B99EE-DF9D-4BC4-85DF-78301D8FAE2F @default.
- Q90668330 P2093 Q90668330-C5CF18EB-C7F0-4675-B03B-CAA90B0AFB9D @default.
- Q90668330 P2093 Q90668330-ECEE7F8F-644A-466C-AE0F-57DD91093478 @default.
- Q90668330 P2093 Q90668330-FFFC6D9A-5889-4921-A8F7-189792064CE6 @default.
- Q90668330 P304 Q90668330-DDE92057-F0BC-47C1-BF3A-F6CACA895F2D @default.
- Q90668330 P31 Q90668330-C3A97428-3B2B-490C-9835-AAFC87DBB595 @default.
- Q90668330 P356 Q90668330-F46DCDB6-9C82-46A0-AE10-B21BA176E434 @default.
- Q90668330 P433 Q90668330-87031930-C12C-41B9-95DD-A9B98F8F3F17 @default.
- Q90668330 P478 Q90668330-D2D84063-8677-4D4C-A4D5-9253675FC520 @default.
- Q90668330 P577 Q90668330-54362346-0901-40CE-937B-3B16B3A29C5E @default.
- Q90668330 P698 Q90668330-5369F9A2-3D91-4EA4-9856-6927BA6A694B @default.
- Q90668330 P921 Q90668330-6098B242-7C3B-401F-9A72-D9399234C97B @default.
- Q90668330 P921 Q90668330-D583C4BE-3FF2-4A13-B68D-4A6B4B318E37 @default.
- Q90668330 P356 J.JTHO.2019.09.008 @default.
- Q90668330 P698 31605797 @default.
- Q90668330 P1433 Q2448056 @default.
- Q90668330 P1476 "A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis" @default.
- Q90668330 P2093 "Haruyasu Murakami" @default.
- Q90668330 P2093 "James Chih-Hsin Yang" @default.
- Q90668330 P2093 "Jianxing He" @default.
- Q90668330 P2093 "Jin Hyoung Kang" @default.
- Q90668330 P2093 "Joo-Hang Kim" @default.
- Q90668330 P2093 "Kazuhiko Nakagawa" @default.
- Q90668330 P2093 "Mauro Orlando" @default.
- Q90668330 P2093 "Pan-Chyr Yang" @default.
- Q90668330 P2093 "Rebecca R Hozak" @default.
- Q90668330 P2093 "Sotaro Enatsu" @default.
- Q90668330 P2093 "Tarun Puri" @default.
- Q90668330 P2093 "Tuan Stevon Nguyen" @default.
- Q90668330 P2093 "Wan Li Zhang" @default.
- Q90668330 P2093 "Ying Cheng" @default.
- Q90668330 P304 "91-100" @default.
- Q90668330 P31 Q13442814 @default.
- Q90668330 P356 "10.1016/J.JTHO.2019.09.008" @default.
- Q90668330 P433 "1" @default.
- Q90668330 P478 "15" @default.
- Q90668330 P577 "2019-10-09T00:00:00Z" @default.
- Q90668330 P698 "31605797" @default.
- Q90668330 P921 Q3658562 @default.
- Q90668330 P921 Q864574 @default.